It is also evident that in particular sub-types of cancer the acquisition of a specific mutation, C250T in the hTERT promoter [54], that supports tumour reactivation has identified the potential for tumours to become ‘addicted’ to IKKα-mediated non-canonical NF-κB signalling thus ‘enabling replicative potential’. Here, NFKB1 is linked to cancer.